| Deferred tax assets |
| |
|
March 31, |
|
| |
|
2016 |
|
|
2015 |
|
| Deferred tax assets: |
|
|
|
|
|
|
|
|
| Net
operating loss carryforwards |
|
$ |
36,454,000 |
|
|
$ |
36,661,000 |
|
| Research
and development tax credit carryforwards |
|
|
1,710,000 |
|
|
|
1,667,000 |
|
| Stock-based
compensation |
|
|
5,083,000 |
|
|
|
4,880,000 |
|
| Reserves
and accruals |
|
|
1,111,000 |
|
|
|
1,731,000 |
|
| Other
deferred tax assets |
|
|
241,000 |
|
|
|
49,000 |
|
| State
income taxes |
|
|
(1,000 |
) |
|
|
(1,000 |
) |
| Basis
difference in assets |
|
|
8,000 |
|
|
|
5,000 |
|
| Total
deferred tax assets |
|
$ |
44,606,000 |
|
|
$ |
44,992,000 |
|
| Deferred tax liabilities: |
|
|
|
|
|
|
|
|
| Unrealized
gain on Ruthigen |
|
|
|
|
|
|
(1,105,000 |
) |
| Net deferred tax asset |
|
|
44,606,000 |
|
|
|
43,887,000 |
|
| Valuation allowance |
|
|
(44,606,000 |
) |
|
|
(43,887,000 |
) |
| Net deferred tax asset |
|
$ |
|
|
|
$ |
|
|
|
| Schedule of income tax expense |
| |
|
Years Ended March 31, |
|
| |
|
2016 |
|
|
2015 |
|
| Income tax (benefit) |
|
$ |
(719,000 |
) |
|
$ |
(2,613,000 |
) |
| Change in valuation allowance |
|
|
719,000 |
|
|
|
2,613,000 |
|
| Net income tax expense |
|
$ |
|
|
|
$ |
|
|
|